MedPath

Study on the effect of rifaximin on cirrhosis

Not Applicable
Conditions
Hepatic encephalopathy (Overt encephalopathy, Covert encephalopathy) Hyperammonemia
Registration Number
JPRN-UMIN000044146
Lead Sponsor
Hokkaido University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
150
Inclusion Criteria

Not provided

Exclusion Criteria

1.Persons with pulmonary tuberculosis and other tuberculosis 2.Those who are pregnant or breastfeeding 3.Those who have been diagnosed with pseudomembranous enteritis 4.Others who are judged by the principal investigator or coordinator to be inappropriate as research subjects

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in ammonia levels due to rifaximin administration
Secondary Outcome Measures
NameTimeMethod
1.Changes in hepatic encephalopathy symptoms before and after administration of rifaximin 2.Changes in NP-test test results before and after administration of rifaximin 3.Changes in bacterial translocation markers before and after administration of rifaximin 4.Changes in muscle mass before and after administration of rifaximin 5.Changes in fecal bacterial flora before and after administration of rifaximin 6.Correlation between ammonia value, various blood test values, and NP-test results 7.Correlation between ammonia value and bacterial translocation marker 8.Correlation between ammonia level and endotoxin and preceptin 9.Relationship between ammonia level and fecal bacterial flora
© Copyright 2025. All Rights Reserved by MedPath